Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study

Bhatt, 2013, The global distribution and burden of dengue, Nature, 496, 504, 10.1038/nature12060 2009 Bhatia, 2013, Changing epidemiology of dengue in South-East Asia, WHO South East Asia J Public Health, 2, 23, 10.4103/2224-3151.115830 Sabchareon, 2012, Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial, Lancet, 380, 1559, 10.1016/S0140-6736(12)61428-7 Simmons, 2012, Dengue, N Engl J Med, 366, 1423, 10.1056/NEJMra1110265 Guzmán, 2002, Dengue: an update, Lancet Infect Dis, 2, 33, 10.1016/S1473-3099(01)00171-2 Huy, 2010, National dengue surveillance in Cambodia 1980–2008: epidemiological and virological trends and the impact of vector control, Bull World Health Organ, 88, 650, 10.2471/BLT.09.073908 Wilder-Smith, 2017, Epidemic arboviral diseases: priorities for research and public health, Lancet Infect Dis, 17, e101, 10.1016/S1473-3099(16)30518-7 Capeding, 2014, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial, Lancet, 384, 1358, 10.1016/S0140-6736(14)61060-6 Hadinegoro, 2015, Efficacy and long-term safety of a dengue vaccine in regions of endemic disease, N Engl J Med, 373, 1195, 10.1056/NEJMoa1506223 Vigne, 2017, Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination, Hum Vaccin Immunother, 13, 2004, 10.1080/21645515.2017.1333211 Villar, 2015, Efficacy of a tetravalent dengue vaccine in children in Latin America, N Engl J Med, 372, 113, 10.1056/NEJMoa1411037 Kinney, 1997, Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53, Virology, 230, 300, 10.1006/viro.1997.8500 Butrapet, 2000, Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3, J Virol, 74, 3011, 10.1128/JVI.74.7.3011-3019.2000 Huang, 2003, Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development, J Virol, 77, 11436, 10.1128/JVI.77.21.11436-11447.2003 Osorio, 2011, Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever, Vaccine, 29, 7251, 10.1016/j.vaccine.2011.07.020 Huang, 2013, Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax), PLoS Negl Trop Dis, 7, e2243, 10.1371/journal.pntd.0002243 Osorio, 2016, A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone, Expert Rev Vaccines, 15, 497, 10.1586/14760584.2016.1128328 George, 2015, Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial, J Infect Dis, 212, 1032, 10.1093/infdis/jiv179 Osorio, 2014, Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study, Lancet Infect Dis, 14, 830, 10.1016/S1473-3099(14)70811-4 Rupp, 2015, Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study, Vaccine, 33, 6351, 10.1016/j.vaccine.2015.09.008 Sirivichayakul, 2016, Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study, J Infect Dis, 213, 1562, 10.1093/infdis/jiv762 Saez-Llorens, 2017, Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study, Lancet Infect Dis, 17, 615, 10.1016/S1473-3099(17)30166-4 Santiago, 2013, Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus, PLoS Negl Trop Dis, 7, e2311, 10.1371/journal.pntd.0002311 Prymula, 2014, Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial, Lancet, 383, 1313, 10.1016/S0140-6736(12)61461-5 Ngai, 1996, Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children, Pediatr Infect Dis J, 15, 49, 10.1097/00006454-199601000-00011 Wellington, 2003, Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella, Drugs, 63, 2107, 10.2165/00003495-200363190-00012 Osorio, 2015, Development of a recombinant, chimeric tetravalent dengue vaccine candidate, Vaccine, 33, 7112, 10.1016/j.vaccine.2015.11.022 Marin, 2016, Global varicella vaccine effectiveness: a meta-analysis, Pediatrics, 137, 1, 10.1542/peds.2015-3741 Soares-Weiser, 2012, Vaccines for preventing rotavirus diarrhoea: vaccines in use, Cochrane Database Syst Rev, 11, 10.1002/14651858.CD008521.pub2